迪瑞医疗
(300396)
| 流通市值：40.90亿 | | | 总市值：40.96亿 |
| 流通股本：2.72亿 | | | 总股本：2.73亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 350,694,494.5 | 182,424,018.64 | 1,217,807,735.16 | 1,175,445,053.92 |
| 营业收入 | 350,694,494.5 | 182,424,018.64 | 1,217,807,735.16 | 1,175,445,053.92 |
| 利息收入 | - | 0 | - | - |
| 已赚保费 | - | 0 | - | - |
| 手续费及佣金收入 | - | 0 | - | - |
| 二、营业总成本 | 372,632,910.6 | 174,838,646.92 | 1,107,954,218.58 | 986,818,603.55 |
| 营业成本 | 214,439,455.14 | 104,388,815.67 | 683,955,656.48 | 665,191,024.53 |
| 利息支出 | - | 0 | - | - |
| 手续费及佣金支出 | - | 0 | - | - |
| 退保金 | - | 0 | - | - |
| 赔付支出净额 | - | 0 | - | - |
| 提取保险合同准备金净额 | - | 0 | - | - |
| 保单红利支出 | - | 0 | - | - |
| 分保费用 | - | 0 | - | - |
| 税金及附加 | 3,993,569.05 | 2,494,529.95 | 11,490,628.81 | 9,690,305.51 |
| 销售费用 | 103,556,013.37 | 40,890,892.69 | 231,537,434.1 | 177,180,126.68 |
| 管理费用 | 26,998,675.61 | 13,354,697.22 | 56,839,267.07 | 34,301,565.3 |
| 研发费用 | 46,858,779.49 | 21,117,372.39 | 130,431,565.75 | 95,643,187.59 |
| 财务费用 | -23,213,582.06 | -7,407,661 | -6,300,333.63 | 4,812,393.94 |
| 其中:利息费用 | 4,902,658.82 | 2,694,928.67 | 8,736,876.51 | 5,843,826.12 |
| 其中:利息收入 | 17,832,116.39 | 2,020,177.25 | 18,872,358.53 | 5,229,684.7 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 131,347.22 | 0 | -185,848.63 | -185,848.63 |
| 加:投资收益 | 8,723,248.04 | 4,429,146.72 | 23,607,377.55 | 20,686,292.54 |
| 净敞口套期收益 | - | 0 | - | - |
| 汇兑收益 | - | 0 | - | - |
| 资产处置收益 | 533,694.81 | 134,425 | 82,446.44 | 0 |
| 资产减值损失(新) | -11,972,447.77 | 81,449.38 | -1,085,123.38 | -2,754,655.98 |
| 信用减值损失(新) | -10,448,128.37 | -711,353.55 | -11,107,671.88 | -11,883,878.16 |
| 其他收益 | 4,467,520.04 | 2,467,311.39 | 22,483,639.93 | 19,617,801.24 |
| 四、营业利润 | -30,503,182.13 | 13,986,350.66 | 143,648,336.61 | 214,106,161.38 |
| 加:营业外收入 | 128,413.12 | 190,689.04 | 3,056,183.69 | 448,539.74 |
| 减:营业外支出 | 670,141.34 | 139,725.81 | 1,016,796.37 | 937,650.95 |
| 五、利润总额 | -31,044,910.35 | 14,037,313.89 | 145,687,723.93 | 213,617,050.17 |
| 减:所得税费用 | -2,727,216.18 | -1,639,889.91 | 3,782,718.32 | 21,050,445.45 |
| 六、净利润 | -28,317,694.17 | 15,677,203.8 | 141,905,005.61 | 192,566,604.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -28,317,694.17 | 15,677,203.8 | 141,905,005.61 | 192,566,604.72 |
| 终止经营净利润 | - | 0 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -28,312,010.46 | 15,678,683.66 | 141,922,552.76 | 192,577,440.82 |
| 少数股东损益 | -5,683.71 | -1,479.86 | -17,547.15 | -10,836.1 |
| 扣除非经常损益后的净利润 | -31,908,614.92 | 13,969,017.91 | 133,755,457.42 | 188,302,693.65 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.1 | 0.06 | 0.52 | 0.71 |
| (二)稀释每股收益 | -0.1 | 0.06 | 0.52 | 0.71 |
| 八、其他综合收益 | 6,789,379.31 | 5,330,335.74 | 3,902,996.17 | 867,601.54 |
| 归属于母公司股东的其他综合收益 | 6,788,915.29 | 5,330,156.79 | 3,903,295.08 | 867,496.48 |
| 九、综合收益总额 | -21,528,314.86 | 21,007,539.54 | 145,808,001.78 | 193,434,206.26 |
| 归属于母公司股东的综合收益总额 | -21,523,095.17 | 21,008,840.45 | 145,825,847.84 | 193,444,937.3 |
| 归属于少数股东的综合收益总额 | -5,219.69 | -1,300.91 | -17,846.06 | -10,731.04 |
| 公告日期 | 2025-08-26 | 2025-04-26 | 2025-03-29 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |